Brief: Hansoh Pharmaceutical Receives Drug Registration Approval Of Second Indication Of Xinyue (Inebilizumab Injection) By NMPA
01/09/2025 16:00
Sept 1 (Reuters) - Hansoh Pharmaceutical Group Company Ltd 3692.HK: DRUG REGISTRATION APPROVAL OF SECOND INDICATION OF XINYUE (INEBILIZUMAB INJECTION) GRANTED BY NMPA CHINA Further company coverage: 3692.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion